MDSpire NewsFDA Expands Pediatric Allergy Nasal Spray Use

📋 Regulatory Action / Label Change

The FDA expanded approval of olopatadine hydrochloride and mometasone furoate nasal spray for seasonal allergic rhinitis to include children ages 6 to 11 years. The decision was supported by a randomized, double-blind, placebo-controlled phase 3 study involving 446 pediatric patients.

Clinical Considerations

• Phase 3 testing demonstrated improved nasal symptom scores versus placebo during a 14-day treatment period.
• The fixed-dose product combines an H1-antihistamine with an intranasal corticosteroid in a single spray.
• The expanded indication lowers the approved treatment age from 12 years to 6 years.
• Labeling includes warnings regarding epistaxis, immunosuppression, adrenal effects, glaucoma, cataracts, and reduced pediatric growth velocity.

Practice Applications

• Recognize the expanded FDA-approved age range for seasonal allergic rhinitis treatment.
• Interpret efficacy findings within the context of a short-term phase 3 trial.
• Monitor growth parameters during prolonged pediatric corticosteroid exposure.
• Consider labeled safety precautions when discussing treatment options with families.